Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JW202313 dry powder inhaler for maintenance treatment of chronic obstructive pulmonary disease
CTR20264027Phase 2Active
- Sponsor
- Shandong Jianwei Pharmaceutical
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JW202313 in chronic obstructive pulmonary disease (COPD), sponsored by Shandong Jianwei Pharmaceutical. Started Nov 2026; status: active.
02
Drugs
JW202313
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20264027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264027.